204 related articles for article (PubMed ID: 35634427)
1. AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.
Hsu CH; Huang YH; Lin SM; Hsu C
Liver Cancer; 2022 Apr; 11(2):94-112. PubMed ID: 35634427
[TBL] [Abstract][Full Text] [Related]
2. Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.
Breitenecker K; Hedrich V; Pupp F; Chen D; Řezníčková E; Ortmayr G; Huber H; Weber G; Balcar L; Pinter M; Mikulits W
Front Oncol; 2023; 13():1238883. PubMed ID: 37746265
[TBL] [Abstract][Full Text] [Related]
3. Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.
Haider C; Hnat J; Wagner R; Huber H; Timelthaler G; Grubinger M; Coulouarn C; Schreiner W; Schlangen K; Sieghart W; Peck-Radosavljevic M; Mikulits W
Hepatology; 2019 Jan; 69(1):222-236. PubMed ID: 30014484
[TBL] [Abstract][Full Text] [Related]
4. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
Arechederra M; Bazai SK; Abdouni A; Sequera C; Mead TJ; Richelme S; Daian F; Audebert S; Dono R; Lozano A; Gregoire D; Hibner U; Allende DS; Apte SS; Maina F
J Hepatol; 2021 Apr; 74(4):893-906. PubMed ID: 33197513
[TBL] [Abstract][Full Text] [Related]
5. PRAME Is a Novel Target of Tumor-Intrinsic Gas6/Axl Activation and Promotes Cancer Cell Invasion in Hepatocellular Carcinoma.
Hedrich V; Breitenecker K; Ortmayr G; Pupp F; Huber H; Chen D; Sahoo S; Jolly MK; Mikulits W
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173882
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
Hara T; Kimura A; Miyazaki T; Tanaka H; Morimoto M; Nakai K; Soeda J
Biochem Biophys Rep; 2020 Mar; 21():100726. PubMed ID: 32055714
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence.
Santoni M; Iacovelli R; Colonna V; Klinz S; Mauri G; Nuti M
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1029-1054. PubMed ID: 34445927
[TBL] [Abstract][Full Text] [Related]
11. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
12. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
13. c-Met expression in renal cell carcinoma with bone metastases.
Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
[TBL] [Abstract][Full Text] [Related]
14. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
15. lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells.
Topel H; Bagirsakci E; Comez D; Bagci G; Cakan-Akdogan G; Atabey N
Cell Commun Signal; 2020 Jul; 18(1):110. PubMed ID: 32650779
[TBL] [Abstract][Full Text] [Related]
16. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
17. Targeted agents for second-line treatment of advanced hepatocellular carcinoma.
Personeni N; Pressiani T; Bozzarelli S; Rimassa L
World J Gastrointest Oncol; 2019 Oct; 11(10):788-803. PubMed ID: 31662820
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
[TBL] [Abstract][Full Text] [Related]
19. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.
Lee HJ; Jeng YM; Chen YL; Chung L; Yuan RH
Carcinogenesis; 2014 Apr; 35(4):769-75. PubMed ID: 24233839
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
